Alfacalcidol-D6

Modify Date: 2024-01-19 16:37:14

Alfacalcidol-D6 structure	Common Name	Alfacalcidol-D6
	CAS Number	1641940-94-4	Molecular Weight	406.674
	Density	1.0±0.1 g/cm3	Boiling Point	531.5±50.0 °C at 760 mmHg
	Molecular Formula	C₂₇H₃₈D₆O₂	Melting Point	N/A
	MSDS	N/A	Flash Point	222.6±24.7 °C

Use of Alfacalcidol-D6

Alfacalcidol-D6, a deuterated Alfacalcidol (1-hydroxycholecalciferol; Alpha D3; 1.alpha.-Hydroxyvitamin D3), is a non-selective VDR activator medication. IC50 value: Target: VDR activatorAlfacalcidol (1-hydroxycholecalciferol; Alpha D3; 1.alpha.-Hydroxyvitamin D3) improves mechanical bone strength and bone mass; suppresses osteoclastic bone resorption in vivo.

Name	Alfacalcidol-D6
Synonym	More Synonyms

Description	Alfacalcidol-D6, a deuterated Alfacalcidol (1-hydroxycholecalciferol; Alpha D3; 1.alpha.-Hydroxyvitamin D3), is a non-selective VDR activator medication. IC50 value: Target: VDR activatorAlfacalcidol (1-hydroxycholecalciferol; Alpha D3; 1.alpha.-Hydroxyvitamin D3) improves mechanical bone strength and bone mass; suppresses osteoclastic bone resorption in vivo.
Related Catalog	Signaling Pathways >> Vitamin D Related >> VD/VDR Research Areas >> Metabolic Disease
References	[1]. Shiraishi et al (2000) Alfacalcidol inhibits bone resorption and stmulates formation in an ovariectomized rat model of osteoporosis: Distinct actions from estrogen. Journal of Bone and Mineral Research. 15 770. [2]. Ringe JD, Schacht E. et al. Prevention and therapy of osteoporosis: the roles of plain vitamin D and alfacalcidol. Rheumatol Int. 2004 Jul;24(4):189-97. [3]. Ivarsen P, Povlsen JV, Christensen KL.Effect of alfacalcidol on cardiac function in patients with chronic kidney disease stage 4 and secondary hyperparathyroidism: A pilot study.Scand J Urol Nephrol. 2012 Jun 25. [4]. Rianthavorn P,et al. Prevention of bone loss in children receiving long-term glucocorticoids with calcium and alfacalcidol or menatetrenone.J Pediatr Endocrinol Metab. 2012;25(3-4):307-12. [5]. Ringe JD, Farahmand P, Schacht E.Alfacalcidol in men with osteoporosis: a prospective, observational, 2-year trial on 214 patients.Rheumatol Int. 2012 Apr 8.

Description

Related Catalog

Signaling Pathways >> Vitamin D Related >> VD/VDR

Research Areas >> Metabolic Disease

References

[1]. Shiraishi et al (2000) Alfacalcidol inhibits bone resorption and stmulates formation in an ovariectomized rat model of osteoporosis: Distinct actions from estrogen. Journal of Bone and Mineral Research. 15 770.

[2]. Ringe JD, Schacht E. et al. Prevention and therapy of osteoporosis: the roles of plain vitamin D and alfacalcidol. Rheumatol Int. 2004 Jul;24(4):189-97.

[3]. Ivarsen P, Povlsen JV, Christensen KL.Effect of alfacalcidol on cardiac function in patients with chronic kidney disease stage 4 and secondary hyperparathyroidism: A pilot study.Scand J Urol Nephrol. 2012 Jun 25.

[4]. Rianthavorn P,et al. Prevention of bone loss in children receiving long-term glucocorticoids with calcium and alfacalcidol or menatetrenone.J Pediatr Endocrinol Metab. 2012;25(3-4):307-12.

[5]. Ringe JD, Farahmand P, Schacht E.Alfacalcidol in men with osteoporosis: a prospective, observational, 2-year trial on 214 patients.Rheumatol Int. 2012 Apr 8.

Density	1.0±0.1 g/cm3
Boiling Point	531.5±50.0 °C at 760 mmHg
Molecular Formula	C₂₇H₃₈D₆O₂
Molecular Weight	406.674
Flash Point	222.6±24.7 °C
Exact Mass	406.371796
LogP	8.31
Vapour Pressure	0.0±3.2 mmHg at 25°C
Index of Refraction	1.534
Storage condition	2-8℃

MFCD22417103

Alfacalcidol-D6

Use of Alfacalcidol-D6

Names

Alfacalcidol-D6 Biological Activity

Chemical & Physical Properties

Synonyms